# Xlumena

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xlumena

- Industry: Medical Devices & Equipment
- Headquarters: Mountain View, US
- Website: www.xlumena.com
- Total disclosed funding: $37M
- Latest round: Series C (Dec 4, 2013)
- Investors on record: 6

## About

Xlumena specializes in innovative medical technologies, particularly in the field of interventional endoscopic ultrasound (EUS) therapeutics, aimed at enhancing patient care through advanced solutions.Xlumena, founded in 2007 and headquartered in Mountain View, US, focuses on developing medical devices for endoscopic ultrasound therapies. In April 2015, the company was acquired by Boston Scientific for USD 75 mn, marking a significant pivot in its business strategy. The company has completed 9 different deals throughout its history, highlighting its active participation in the medical technology sector. The founder's history is not provided, and there is no mention of subsidiaries or further funding rounds.Through Boston Scientific's acquisition, Xlumena provides innovative solutions in interventional endoscopic ultrasound (EUS) therapeutics. Their flagship product, AXIOS stents, facilitates minimally invasive procedures for conditions like pancreatic fluid collections and biliary obstructions, mainly utilized by healthcare professionals in hospitals and specialized medical facilities across Europe and the United States.Boston Scientific generates revenue from the direct sales of medical devices, including AXIOS stents, to healthcare providers and institutions. The business operates on a B2B model, with pricing guided by market demands and regulatory considerations. Revenue streams are sustained by the volume of devices sold and their application in surgical procedures, ensuring a stable transaction flow with their professional clients.Xlumena's recent acquisition by Boston Scientific aims to leverage its resources for product innovation and market expansion. Although specific upcoming products are not detailed, the intention to enhance the product lineup is evident. The company looks to expand its market presence further into regions outside its current operational territories. The USD 75 mn funding from the acquisition will likely support these strategic initiatives, although no specific plans or timelines are mentioned for new product launches or geographic expansions.

## Funding rounds

- Series C, Dec 4, 2013, $21M — Prism Venture Management, Charter Life Sciences, Aperture Venture Partners, Ascent Biomedical Ventures, Third Point
- Series B, Apr 28, 2011, $7M — Prism Venture Management, Charter Life Sciences, Western Technology Investment, Aperture Venture Partners, Ascent Biomedical Ventures
- Series A, May 11, 2010, $3M — Prism Venture Management, Charter Life Sciences, Ascent Biomedical Ventures
- Series A, May 16, 2008, $6M — Prism Venture Management, Charter Life Sciences, Ascent Biomedical Ventures

## Investors

- Prism Venture Management (https://capitalatlas.ai/funds/prism-venture-management) — Series A, Series B, Series C
- Charter Life Sciences (https://capitalatlas.ai/funds/charter-life-sciences) — Series A, Series B, Series C
- Ascent Biomedical Ventures (https://capitalatlas.ai/funds/ascent-biomedical-ventures) — Series A, Series B, Series C
- Western Technology Investment (https://capitalatlas.ai/funds/western-technology-investment) — Series B
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series B, Series C
- Third Point (https://capitalatlas.ai/funds/third-point) — Series C